Synoligo Biotechnologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Synoligo Biotechnologies is a specialized contract research organization (CRO) focused on high-complexity custom oligonucleotide synthesis. Leveraging a team with deep expertise and proprietary SynOptuma™ technology, the company targets niche applications in synthetic biology, diagnostics, and therapeutics that require non-standard modifications and scales. Its value proposition centers on mastering complex projects, offering rapid turnaround, and providing a vast library of modifications, serving biotech startups, diagnostic firms, and pharmaceutical companies.

Genetics & GenomicsSynthetic Biology

Technology Platform

Proprietary SynOptuma™ oligonucleotide synthesis platform enabling high-quality production of over 500+ modifications, complex conjugates (lipids, dendrimers), ultra-long sequences (up to 200nt), and scale from nmol to 100+ gram batches with guaranteed ultra-low endotoxin levels.

Opportunities

The rapid growth of genetic medicines (RNAi, antisense, CRISPR, mRNA) creates sustained demand for high-quality, complex oligos.

Synoligo can capitalize on its niche expertise to become the preferred partner for biotech startups and pharma companies requiring specialized, therapeutic-grade oligonucleotides.

Expansion into adjacent service areas like analytical development or formulation could further increase its value proposition.

Risk Factors

The company's reliance on a niche, complex project market makes it vulnerable to client program failures and competitive entry by larger, well-funded CDMOs.

As a private company, scaling manufacturing and R&D to meet demand may be constrained by access to capital.

Supply chain disruptions for key synthesis reagents pose a persistent operational risk.

Competitive Landscape

Synoligo competes against large-scale 'big box' oligo vendors (e.g., IDT, Thermo Fisher, Eurofins) for standard products but differentiates in the high-complexity niche. It also competes with other specialized CROs and CDMOs focusing on oligonucleotides. Its key competitive advantages are its deep technical expertise, willingness to tackle 'impossible' projects, fast turnaround, and vast modification portfolio.

More companies in Biologics / Biosimilars →More companies in United States →